Phathom Pharmaceuticals (PHAT) Net Income towards Common Stockholders: 2022-2025
Historic Net Income towards Common Stockholders for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Sep 2025 value amounting to -$30.0 million.
- Phathom Pharmaceuticals' Net Income towards Common Stockholders rose 64.98% to -$30.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$274.4 million, marking a year-over-year increase of 19.14%. This contributed to the annual value of -$334.3 million for FY2024, which is 65.99% down from last year.
- According to the latest figures from Q3 2025, Phathom Pharmaceuticals' Net Income towards Common Stockholders is -$30.0 million, which was up 60.39% from -$75.7 million recorded in Q2 2025.
- Phathom Pharmaceuticals' Net Income towards Common Stockholders' 5-year high stood at -$30.0 million during Q3 2025, with a 5-year trough of -$94.3 million in Q1 2025.
- Moreover, its 3-year median value for Net Income towards Common Stockholders was -$75.7 million (2025), whereas its average is -$66.9 million.
- As far as peak fluctuations go, Phathom Pharmaceuticals' Net Income towards Common Stockholders tumbled by 123.20% in 2024, and later skyrocketed by 64.98% in 2025.
- Phathom Pharmaceuticals' Net Income towards Common Stockholders (Quarterly) stood at -$55.0 million in 2022, then plummeted by 44.76% to -$79.6 million in 2023, then increased by 6.36% to -$74.5 million in 2024, then surged by 64.98% to -$30.0 million in 2025.
- Its last three reported values are -$30.0 million in Q3 2025, -$75.7 million for Q2 2025, and -$94.3 million during Q1 2025.